C2N to develop method for early identification of Alzheimer’s disease

C2N Diagnostics has acquired the exclusive worldwide commercial rights to the intellectual property associated with blood biomarkers for Alzheimer’s and will develop them for clinical diagnostic applications. Credit : Business Wire.



  • C2N